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High-resolution proton nuclear magnetic resonance studies show that the spectrum of a proteolipid com- 
plex, isolated from the serum of patients with malignant diseases, is directly comparable with that obtained 
from intact cancer cells and solid tumours. These NMR signals have previously been shown to reveal differ- 
ences between cancer cells with various biological characteristics such as metastatic apacity and drug sensi- 
tivity. The proteolipid contains cholesterol, phospholipid, triglyceride, glycolipids, ether-linked lipids, and 
an apoprotein of unusual electrophoretic mobility. We have yet to confirm the presence of the mRNA re- 
ported by others. NMR spectroscopy could be used as a rapid method of identifying the presence of this 
proteolipid complex in human serum and aiding the diagnosis of malignant disease. 
NMR Proteolipid (Human serum) Malignancy 
1. INTRODUCTION 
High-resolution ‘H NMR signals from cancer 
cells correlate with their metastatic ability [l] and 
drug sensitivity [2] as well as being able to show 
malignant change prior to histological identifica- 
tion [3]. The origin of the NMR signal is the 
plasma membrane [4] and 2D NMR methods iden- 
tify neutral lipid as being primarily responsible for 
this spectrum [5]. Lipoprotein complexes which 
have a core of neutral lipid [6] have been shown to 
have similar yet different characteristics to the 
plasma membrane lipid domain responsible for the 
high-resolution NMR spectra from malignant cells 
[7]. An RNA-proteolipid complex has recently 
been isolated from the serum of patients with 
malignant diseases and in the medium from 
cultures of malignant cells [8]. 
We have isolated a proteolipid and the remain- 
ing lipoproteins from the plasma of a patient with 
an ovarian tumour. The various lipoproteins, pro- 
teolipid, and a tumour biopsy have been studied by 
NMR methods. The proteolipid complex has been 
* To whom correspondence should be addressed 
characterised further by lipid analysis, electron 
microscopy and biochemical assays. 
2. MATERIALS AND METHODS 
2.1. Isolation of lipoproteins and proteolipid 
The total lipoprotein fraction was isolated as 
described by Goldstein et al. [9] from the serum of 
a patient with an ovarian cancer. An opalescent 
band, visible between LDL and HDL and contain- 
ing the proteolipid complex, was isolated from the 
total lipoprotein fraction on a KBr gradient [8]. 
2.2. Chemical analysis 
Total protein, lipid, triglyceride, phospholipid, 
free and esterified cholesterol were measured as 
described in [l]. RNA was determined by the or- 
cinol method [lo] with corrections for glycolipid 
interference. Extraction and quantitation of 
gangliosides (assumed to be mainly monosia- 
loganglioside as judged by thin-layer chroma- 
tography) were performed as described [l 11. 
Neutral glycosphingolipid was estimated by the or- 
cinol method [12]. Total 0-alkyl and 0-alkenyl 
glycerolipids were determined as already reported 
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[ 131. Isolated lipoproteins and proteolipid were ex- 
amined by electrophoresis on 1% agarose with 1 M 
barbital buffer, pH 9.0. Gels were stained with oil 
red 0 and positions of apo A- and apo B- 
containing lipoproteins were ascertained from a 
normal plasma control. 
2.3. Electron microscopy 
Particles were examined by negative-staining 
electron microscopy. The preparations were 
stained with 1% sodium phosphotungstate (pH 
7.3) and the electron micrographs obtained with a 
Philips 400 electron microscope, operating at 
100 kV and a maximum working magnification of 
x 92000. For the distribution of particle 
diameters, 400 particles were measured from elec- 
tron micrographs. 
2.4. NMR spectroscopy 
‘H NMR spectra were recorded at 37°C using a 
Bruker WM-400 spectrometer equipped with an 
Aspect 2000 computer. 2D scalar correlated spec- 
troscopy (COSY) experiments [14] and Ti and T2 
measurements [ 151 have been described. 
2.5. Enzyme studies 
Either RNase A (0.024 IU, Sigma, EC 3.1.1.34) 
or lipoprotein lipase (4.2 IU, bovine pancreas, 
Boehringer-Mannheim, EC 3.1.27.5) was added to 
1 ml of proteolipid complex which contained 
367 pg protein, and incubated for 1 h at 37°C 
prior to NMR study. 
3. RESULTS AND DISCUSSION 
3.1. Chemical analysis 
The lipid, protein, and nucleic acid content of 
the band containing the proteolipid complex and 
the remaining lipoproteins isolated from the serum 
are shown in table 1. The composition of the 
isolated proteolipid complex is similar to that 
reported by Wieczorek et al. [8] except for a con- 
siderably smaller RNA content as measured by the 
orcinol method. This method does not confirm the 
presence of intact mRNA, since it detects only 
ribose. In addition, triglyceride and ether-linked 
lipids as well as gangliosides and an apoprotein 
with an unusual electrophoretic mobility (> pre-fi) 
are present in this complex (table 1). 
Glycolipid, both neutral and acidic, constitutes 
20% of the proteolipid complex. It is also present 
in the LDL (23%) and HDL (11.2%) fractions of 
the plasma. Glycolipids are only present in trace 
amounts in lipoproteins from healthy donors [ 161. 
However they have been found in neoproteolipids 
W and S [17] which were isolated from tumours 
Table 1 
Lipoprotein and proteolipid complexes isolated from the plasma of a patient with an ovarian tumour 
Size Longest Percentage of total weight 
(nm) TZ (ms) 
RNA Protein Trigly- Gangli- Neutral Phos- Cholesterol Ether- 
ceride oside glyco- pho- linked 
sphingo- lipid Free Ester- lipid 
lipid ified 
VLDL and 
chylomicraa 26-156 188 - apo B 
LDL 19- 23 111 nil apo B 15.7 14.2 1.1 21.9 26.8 6.6 13.2 0.4 
Proteolipid 22- 25 852 4.1 apo A 13.5 4.5 15.5 25.2 6.1 10.7 0.4 
and apo B 19.9 
8- 11 unknown 
HDL 6- 9 154 nil apo A 45.2 8.7 1.3 9.9 23.8 1.9 8.4 0.6 
a Protein and lipid not quantitated due to a low yield 
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and the serum of cancer patients. The relationship 
between the nucleic acid containing proteolipid 
and the neoproteolipid complexes is unclear since 
no nucleic acid analysis was undertaken on the 
latter. 
3.2. Electron microscopy 
From electron micrographs two particle sizes, 
8-l 1 and 22-25 nm, in approximately equal 
numbers were identified in the opalescent band 
containing the proteolipid complex. We consider 
these two particle types to differ from the conven- 
tional LDL and HDL, since unusual elec- 
trophoretic mobility is observed in the opalescent 
band but not in LDL or HDL bands which are 
located on either side (table 1). 
3.3. NA4R spectroscopy 
The NMR method used to distinguish metastatic 
cells from their malignant but non-metastatic 
counterparts in rats is the Meiboom-Gill modifica- 
tion of the Carr-Purcell (CPMG) pulse sequence 
which provides a spin-spin (7’2) relaxation time 
[ 151. In metastatic cells the longest TZ is of the 
order of 0.4-l s whereas in non-metastatic ells 
and normal serum lipoproteins [7] it is less than 
0.25 s [I]. 
The ‘H NMR spectra and TZ relaxation profiles 
of resonances in the methylene region are shown in 
fig.1 for the total plasma lipoproteins (including 
the proteolipid complex), the isolated proteolipid 
complex alone and VLDL and LDL, from the 
same patient. Only the proteolipid complex has a 
long TZ relaxation value of 0.85 s which contrasts 
with the lipoproteins which are all less than 0.2 s 
(table 1). Resonances c and d in the spectrum of 
the proteolipid, both of which have a long Tz, are 
not present in the spectrum of any conventional 
lipoproteins. This long T2 can be measured not on- 
ly in the isolated complex and total lipoprotein 
fraction, but also in the serum and the tumour 
itself. Biopsy samples of tumours on both ovaries 
from this patient were examined and T2 values of 
0.85 and 0.65 s recorded. 
Cells and tumours both gave identical values for 
the selective and non-selective spin-lattice ( TI) 
relaxation experiments [15]. The same phenome- 
non was observed for the proteolipid complex 
where the Tl was found to be 0.45 s. These 
measurements rule out either diffusion or spin ex- 
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Fig.1. 400 MHz ‘H NMR spectra of the methylene 
region of: total lipoprotein fraction (including the 
proteolipid complex) isolated from the plasma (1); the 
opalescent band (containing the proteolipid complex) 
isolated from the total lipoprotein fraction on a KBr 
gradient [8] (2); lipoproteins (LDL and VLDL) which 
were isolated from the same plasma sample (3). The 
spectra are resolution enhanced by the Lorentzian- 
Gaussian method described in [ 151 using LB = - 12; 
GB = 0.08. Below the NMR spectra the results of the 
CPMG TZ relaxation experiment executed as described 
in [15] are shown. The natural og of each peak height 
is plotted against the delay between the first pulse and 
the nth echo. The T2 values are calculated using a least 
squares method where 4 > 0.98. The longest T2 (ms) 
values of each profile are as follows: (1) a = 84, b = 181, 
c = 730, d = 660, e = 226; (2) a = 68, b = 63, c = 671, 
d = 970; (3) VLDL = 188, LDL = 111. 
change between the molecules generating the spec- 
trum. This was not the case for LDL or HDL from 
healthy donors where not only did the selective and 
non-selective measurements differ but a non- 
exponential decay was observed in the selective TI 
experiment [7]. This is an interesting comparison 
since the proteolipid is isolated between these two 
fractions on the KBr gradient. Nevertheless it is 
another physical measurement whereby the cells 
and tumours show identical behaviour to the pro- 
teolipid complex. 
Attempts were made to identify the origins of 
the four methylene resonances which occur at 1.33, 
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1.31, 1.28 and 1.26 ppm in the spectrum of the 
proteolipid complex. RNase A had no effect on 
any of these resonances. This is consistent with the 
report by Wieczorek et al. [8] that RNase did not 
affect the nucleic acid content of the intact parti- 
cle. Lipoprotein lipase, which degrades tri- 
glycerides caused resonances a and b at 1.26 and 
1.28 ppm to decrease significantly in intensity. 
These two resonances have a short TZ of less than 
200 ms. 
The assignment of resonances a and b to 
triglyceride is confirmed by 2D NMR methods 
(fig.2). 2D scalar correlated spectroscopy (COSY) 
methods allow assignment of resonances based on 
spin-spin (scalar) coupling. The off diagonal cross 
peaks denoted A-G (fig.2) indicate spin-spin 
coupling between protons on adjacent atoms. 
The presence of cross peaks A-E (as summa- 
rised in scheme l), and the cross peak G’ (at 
4.3 ppm) which is unique to triglyceride, indicate 
the presence of this neutral lipid. In contrast to the 
cell spectrum, the assignments for which have been 
documented previously [5], cross peak F is not 
s FE BC D D CB A 
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Fig.2. ‘H NMR spectra (400 MHz) of: proteolipid complex isolated on a KBr gradient [8] from the lipoprotein fraction 
of a patient with an ovarian tumour. Suspended in NaCVD20 (1); a suspension of the rat mammary adenocarcinoma 
J clone cells (1 x 10s) suspended in PBS/D20 (2). The one-dimensional spectra, transformed with a 3 Hz line 
broadening, are shown above the 2D scalar correlated spectroscopy (COSY) spectra executed as described in [14]. A 
Gaussian window function was applied in the tz domain (LB = - 16; GB = 0.22) and a Sine-bell in the tl domain. Lipid 
acyl chain and glycerol connectivities assigned A-G are shown in scheme 1. Z denotes the cross peak between the methyl 
and methine protons of the alkyl side chain of the cholesterol ring system. Y is yet to be identified. The arrows in the 
cell spectrum point to cross peaks previously assigned to metabolites in the cell’s cytoplasm (51. 
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observed in the spectrum of the proteolipid com- 
plex. The absence of this cross peak is likely to be 
due to a lack of signal since G’ is only just ob- 
servable and triglyceride accounts for 18% of the 
total lipid in the proteolipid complex. Resonances 
c and d at 1.33 and 1.31 ppm have yet to be 
definitively assigned, but have chemical shifts con- 
sistent with the cross peak Y (fig.2). 
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We conclude that a proteolipid complex similar 
to that reported by Wieczorek et al. [8] accounts 
for almost all of the NMR signals from the plasma 
membrane of cancer cells, and for the unusually 
long TZ relaxation value. Our data strongly suggest 
that a proteolipid is the plasma membrane lipid do- 
main that gives high-resolution ‘H NMR signals. 
The presence of a proteolipid complex containing 
nucleic acid in the plasma membranes may provide 
an interesting explanation for the altered biological 
status of cancer cells as observed by NMR. 
Furthermore, these observations may be rele- 
vant in NMR imaging which currently does not 
satisfactorily distinguish malignant from benign 
tumours [ 181. Our data suggest hat depending on 
the amount of proteolipid present in a tumour and 
its surrounds, the TZ relaxation value will have 
contributions from this complex and may 
therefore be useful in tumour imaging. 
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